266 related articles for article (PubMed ID: 17054242)
1. Terlipressin for hepatorenal syndrome.
Gluud LL; Kjaer MS; Christensen E
Cochrane Database Syst Rev; 2006 Oct; (4):CD005162. PubMed ID: 17054242
[TBL] [Abstract][Full Text] [Related]
2. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
Israelsen M; Krag A; Allegretti AS; Jovani M; Goldin AH; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011532. PubMed ID: 28953318
[TBL] [Abstract][Full Text] [Related]
3. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.
Allegretti AS; Israelsen M; Krag A; Jovani M; Goldin AH; Schulman AR; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD005162. PubMed ID: 29943803
[TBL] [Abstract][Full Text] [Related]
4. Terlipressin for hepatorenal syndrome.
Gluud LL; Christensen K; Christensen E; Krag A
Cochrane Database Syst Rev; 2012 Sep; (9):CD005162. PubMed ID: 22972083
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
6. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis.
Best LM; Freeman SC; Sutton AJ; Cooper NJ; Tng EL; Csenar M; Hawkins N; Pavlov CS; Davidson BR; Thorburn D; Cowlin M; Milne EJ; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD013103. PubMed ID: 31513287
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
Gifford FJ; Morling JR; Fallowfield JA
Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
[TBL] [Abstract][Full Text] [Related]
8. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
Wang H; Liu A; Bo W; Feng X; Hu Y
Medicine (Baltimore); 2018 Apr; 97(16):e0431. PubMed ID: 29668606
[TBL] [Abstract][Full Text] [Related]
9. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
Solanki P; Chawla A; Garg R; Gupta R; Jain M; Sarin SK
J Gastroenterol Hepatol; 2003 Feb; 18(2):152-6. PubMed ID: 12542598
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: terlipressin therapy for the hepatorenal syndrome.
Fabrizi F; Dixit V; Martin P
Aliment Pharmacol Ther; 2006 Sep; 24(6):935-44. PubMed ID: 16948805
[TBL] [Abstract][Full Text] [Related]
12. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
Sagi SV; Mittal S; Kasturi KS; Sood GK
J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
[TBL] [Abstract][Full Text] [Related]
13. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
14. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
15. Terlipressin for acute esophageal variceal hemorrhage.
Ioannou G; Doust J; Rockey DC
Cochrane Database Syst Rev; 2003; (1):CD002147. PubMed ID: 12535432
[TBL] [Abstract][Full Text] [Related]
16. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.
Nassar Junior AP; Farias AQ; D' Albuquerque LA; Carrilho FJ; Malbouisson LM
PLoS One; 2014; 9(9):e107466. PubMed ID: 25203311
[TBL] [Abstract][Full Text] [Related]
17. Terlipressin in hepatorenal syndrome.
Mazur JE; Cooper TB; Dasta JF
Ann Pharmacother; 2011 Mar; 45(3):380-7. PubMed ID: 21386023
[TBL] [Abstract][Full Text] [Related]
18. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
19. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
Uriz J; Ginès P; Cárdenas A; Sort P; Jiménez W; Salmerón JM; Bataller R; Mas A; Navasa M; Arroyo V; Rodés J
J Hepatol; 2000 Jul; 33(1):43-8. PubMed ID: 10905585
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
